Fig. 1S HPLC-HREIMS spectra of marchantin A.
Blue: 210 nm Yellow: 254 nm Pink: Mass spectrum Conditions: Agilent 1100 system consisting of degasser, quaternary pump, auto sampler, column oven, photodiode array detector (PDA) and a 150 × 4.6 mm Phenomenex C18 Luna column with particle size of 5 µm and pore size of 100 Å (Phenomenex, Inc.). The column was operated at 40°C. Solvent was delivered at 0.5 mL/min using the following linear gradient elution profile: 50% B to 100% B over 30 min (solvent A: water/acetonitrile 95:5 + 0.1% formic acid; solvent B: acetonitrile/water 95:5 + 0.1% formic acid). The flow from the column was split by a T-piece connected to capillaries of different length and i.d. (10 cm/0.05 µm, 100 cm/0.5 µm), directing < 1% of the column outflow to a micrOTOF-Q mass spectrometer equipped with electrospray ionization (ESI) interface (Bruker Daltonik GmbH). Mass spectra were acquired in positive-ion mode, using drying temperature of 350 °C, nebulizer pressure of 15 psi, and drying gas flow of 15 mL/min. Injection volume was 5 µL.
Fig. 2S
1 H and 13 C NMR spectra of marchantin A (CDCl 3 , 400.13 and 100.613 MHz). Table 2S Table showing Filename: 
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Table 4S
Results from flow cytometry after PI staining of cell lines T47D, MCF7, and A256, including 
